Pharmacovigilance is the study and practise concerned with the identification, evaluation, comprehension, and avoidance of side effects or any other issue with drugs or vaccines. Before being approved for use, all medications and vaccines go through extensive clinical trials to test their safety and efficacy.
However, the clinical trial procedure entails observing these goods for a brief period of time in a relatively small number of carefully chosen people. Only when these drugs have been used by a diverse population, including those who have other concomitant ailments, for an extended length of time may certain adverse effects become apparent. Information obtained from patients and healthcare providers through Pharmacovigilance agreements, as well as from other sources such as the medical literature, is critical in providing the data required for pharmacovigilance. In most countries, adverse event data received by the licence holder (typically a pharmaceutical company) must be submitted to the local drug regulatory authority before a pharmaceutical product can be marketed or tested. Finally, Pharmacovigilance is concerned with identifying the risks associated with pharmaceutical products and mitigating the risk of harm to patients. To ensure compliance with global laws, regulations, and guidance, companies must conduct a comprehensive drug safety and pharmacovigilance audit. Adverse event reporting is the activity that is most frequently connected to Pharmacovigilance and that uses a large amount of resources for drug regulatory authorities (or comparable governmental organisations) and drug safety departments in pharmaceutical corporations. Receiving, sorting, entering data, evaluating it, distributing it, reporting (if necessary), and archiving adverse event (AE) data and documentation are all part of AE reporting. Initiated reports from patient support programmes, reports from clinical or post-marketing studies, reports from literature sources, reports from the media (including social media and websites), and reports submitted directly to drug regulatory agencies are all possible sources of AE reports. Most nations have regulations requiring AE reporting for pharmaceutical companies. AE reporting also provides data to these companies and drug regulatory authorities, which are critical in determining a drug's risk-benefit profile. Several aspects of AE reporting are as follows: One of the fundamental principles of adverse event reporting is determining what constitutes an individual case safety report Pharmacovigilance. It is critical to determine whether the "four elements" of a valid individual case safety report are present during the triage phase of a potential adverse event report: (1) an identifiable patient, (2) an identifiable reporter, (3) a suspect drug, and (4) an adverse event. The case is not a legitimate individual case safety report if one or more of these four components is missing. There are no exceptions to this rule, yet there might be some situations where a decision must be made. For instance, the definition of "identified" may not necessarily be precise. Even when the patient is not clearly identified, the report is still valid if a doctor says they have a patient X taking medicine Y who suffered Z (an AE), Pharmacovigilance but they won't give any more details. This is true because the reporter is recognisable to the doctor as a genuine person and has first-hand knowledge of the patient. Identification is crucial to avoid multiple reporting of the same information.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2023
Categories
All
|